Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261957 | 0.80 | MAPT (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL938402 | 0.79 | RAF1 (0.58) | ALDH1A1SMN1; SMN2RAF1MAPTKDR | |
| SCHEMBL4243012 | 0.75 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2RAF1MAPTKDR | |
| SCHEMBL12719566 | 0.74 | RAB9A (0.46) | ALDH1A1RAF1MAPTKDRKMT2A | |
| SCHEMBL936531 | 0.74 | MAPK14 (0.54) | ALDH1A1SMN1; SMN2RAF1MAPTKDR | |
| SCHEMBL4181174 | 0.74 | RET (0.56) | RAF1KDRKMT2AMEN1MAPK1 | |
| SCHEMBL937860 | 0.73 | RAF1 (0.56) | SMN1; SMN2RAF1MAPTKDRKMT2A | |
| SCHEMBL6956521 | 0.72 | MAPT (0.42) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL13556578 | 0.69 | BRAF (0.55) | TRPV1RAF1MAPTKDRKMT2A | |
| SCHEMBL4173358 | 0.69 | RAF1 (0.52) | SMN1; SMN2RAF1MAPTKDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | ALDH1A1 1345/4885TRPV1 3391/4885SMN1; SMN2 4480/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | ALDH1A1 735/4885TRPV1 2596/4885SMN1; SMN2 4039/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | ALDH1A1 1345/4885TRPV1 3391/4885SMN1; SMN2 4480/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | ALDH1A1 1345/4885TRPV1 3391/4885SMN1; SMN2 4480/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | ALDH1A1 1345/4885TRPV1 3391/4885SMN1; SMN2 4480/4885 |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | ALDH1A1 1655/4885TRPV1 4864/4885SMN1; SMN2 3692/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | ALDH1A1 1255/4885TRPV1 4037/4885SMN1; SMN2 4628/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | ALDH1A1 1345/4885TRPV1 3391/4885SMN1; SMN2 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.